Compliance and efficacy of extended release Metformin and immediate release thrice daily Metformin in type-2 Diabetes Mellitus- A comparative study

Aim of study: Metformin is a first-line pharmacological treatment for patients with type 2 diabetes mellitus because of its favorable overall profile, including its glucose-lowering ability, weight-neutral effects, and low risk of hypoglycemia; however, gastrointestinal (GI) intolerance may limit use in some patients. Extendedrelease metformin improves GI tolerability, allows once-daily dosing,improves compliance in patients. Conclusion: Patients with type 2 DM who had been receiving thrice daily MIR achieved comparable glycemic control when therapy was switched to once or twice daily MXR at the same daily dose.